Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Scientific Contributions

Low-Renin and Nonmodulating Essential Hypertension

David G. Warnock
Download PDF
https://doi.org/10.1161/01.HYP.34.3.395
Hypertension. 1999;34:395-397
Originally published September 1, 1999
David G. Warnock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
Loading
  • blacks
  • renin
  • aldosterone
  • endothelial sodium channel
  • Liddle’s syndrome

Low-renin hypertension (LREH) accounts for an important subset of the hypertensive human population and is associated with salt-sensitivity and diuretic response and is also common in black patients. An interesting finding in LREH is the presence of normal plasma aldosterone levels.1 2 The ratio of plasma aldosterone to renin activity is used to screen for adrenal adenomas and hyperplasia3 and is usually >100 when plasma renin activity is expressed in ng/mL/hr and the aldosterone concentration is expressed in ng/dL. The plasma aldosterone/plasma renin activity ratios may be somewhat elevated in LREH (>30 but <100), which is especially relevant if the concurrent urinary sodium excretion exceeds 200 mEq/24 hours.4 It is not known what regulates aldosterone secretion in this setting or whether there is actual mineralocorticoid excess. Undue prior emphasis may have been placed on the continued suppression of plasma renin activity during severe salt restriction or volume depletion in LREH,1 and the suppression of plasma renin activity and basal aldosterone secretion5 in the elderly can also confound the analysis of LREH.

Studies by Fisher et al2 focus on adrenal and pressor responsiveness to angiotensin II (Ang II) as a function of dietary salt intake in patients with LREH, normal-renin hypertension, and normal controls. Especially striking are the functional similarities between LREH and “ nonmodulating” essential hypertension with normal plasma renin activity (NMEH), including: (1) salt-sensitivity of the blood pressure; (2) blunted plasma aldosterone responses to Ang II infusion and upright posture after 5 days of rigid dietary sodium restriction; and (3) relatively low basal plasma aldosterone levels. These differences compared with normal controls and “modulating” hypertensive subjects disappeared when the dietary salt intake was increased to 200 mEq. The latter results are consistent with suppression of plasma Ang II activity during high-salt intake with resensitization of Ang II receptors and improved Ang II responsiveness. If so, then perhaps the blunted responsiveness to Ang II during sodium restriction could reflect the continuing formation of Ang II, with angiotensin receptor downregulation.

Fisher et al2 based the definition of LREH and the Ang II responsiveness on patients who had undergone 5 days of sodium salt restriction (10 mEq/24 hours) rather than “short” protocols with concomitant diuretic administration. It is important to determine if the subjects had actually come into sodium balance because that would affect the interpretation of the basal plasma aldosterone levels. The low basal plasma aldosterone levels in the LREH and NMEH subjects could have reflected relative volume expansion despite the dietary salt restriction. In this regard, at 5 days, the 24-hour urinary sodium excretion rates were slightly (and significantly) higher in these 2 groups compared with the normal controls and normal-modulating hypertensive subjects (See Table 1 in Reference 22 ).

Our understanding of renal tubule transport defects has expanded in the last several years, providing unique insights into epithelial transport processes and clinical syndromes that result from mutations of these transporters.6 A major focus of these studies has been the epithelial sodium channel (ENaC), which is the rate-limiting barrier for regulating sodium absorption in the mineralocorticoid-responsive renal collecting tubule.7 ENaC can be directly affected by mutations or by changes in the response to or production of mineralocorticoids.8 9 As a result, we now have defined Mendelian syndromes in which ENaC activity is “dysregulated” with subsequent development of disorders of systemic blood pressure that can be attributed to a primary renal mechanism. The mutations that directly affect the subunits of the ENaC channel can result in gain of function (Liddle’s syndrome) or loss of function (pseudohypoaldosteronism type 1), with the predictable clinical phenotype in the affected individuals.6 The normal response to dietary salt surfeit is downregulation of ENaC activity so that sodium reabsorption by the collecting tubule is reduced; any impairment in this process would account for dysregulation of ENaC activity, continuing sodium reabsorption, and volume expansion.

The original descriptions of genetically-proven Liddle’s syndrome involved whites.10 11 With the re-emphasis of the clinical phenotype,12 it was quickly appreciated that patients of African ancestry could also be defined with severe low renin hypertension and markedly suppressed aldosterone secretion, often with hypokalemic metabolic alkalosis.13 Despite the promise of defining a cause of LREH in this important target population, numerous screening efforts of various ethnic populations have not changed the original view that Liddle’s syndrome, with striking suppression of aldosterone secretion, is a rare cause of human LREH. Although there are polymorphisms in the ENaC subunits that can be associated with enhanced ENaC sensitivity to CAMP14 and/or associated with suppressed plasma renin activity,15 6 this accounts for a small proportion of black patients with LREH.

Liddle’s syndrome can be regarded as the phenotypic extreme of LREH, with clear-cut salt-sensitive hypertension.17 In the original studies of the index case, aldosterone secretion was markedly suppressed, accounting for the descriptor “pseudoaldosteronism.”17 18 The index case developed renal failure 25 years after the original description and underwent successful renal transplantation that reversed the clinical phenotype of Liddle’s syndrome.12 Two years after transplantation, her plasma renin activity and aldosterone levels were restored to normal, with appropriate responses to postural changes and dietary salt restriction. These findings demonstrated that the suppression of the plasma renin activity in Liddle’s syndrome was the result of the gain of function mutation in the ENaC complex. The continued suppression of aldosterone excretion despite vigorous dietary salt restriction18 is best explained by chronic suppression of adrenal aldosterone synthase activity as a consequence of chronic volume expansion.8 Of note, in the studies by Fisher et al,2 5 days of dietary salt restriction restored the normal pressor response to Ang II in LREH and NMEH despite continued blunting of the plasma aldosterone response. It would seem likely that aldosterone synthase activity was still somewhat suppressed in these subjects after 5 days of salt restriction, secondary to their chronic volume expanded state.8 Studies of urinary aldosterone excretion, as well as other urinary steroid metabolites of the 18-hydroxylase as a function of chronic dietary salt intake, would be of interest in LREH and NMEH and would directly examine the activity of aldosterone synthase in these subjects.

It can be argued that an important pathophysiological mechanism in LREH could be enhanced renal salt absorption mediated by an activated ENaC complex, with subsequent volume expansion and suppression of plasma renin activity. Such activation could be the primary result of a mutation or polymorphism in the ENaC complex or mineralocorticoid receptor response pathways or may reflect the relative excess of endogenous mineralocorticoid. In contrast to Liddle’s syndrome in which there is a striking suppression of plasma renin activity and aldosterone activity, most subjects with LREH have relatively normal plasma aldosterone levels despite suppressed plasma renin activity. Similar findings have been reported for black LREH patients with the T594M polymorphism of the β ENaC subunit;15 the degree of volume expansion in these patients may be sufficient to suppress plasma renin activity but not sufficient to reduce aldosterone synthase activity. If correct, then the underlying pathophysiological process would be ENaC dysregulation and volume expansion, with second order effects on plasma renin activity and aldosterone synthase activity. In this context, the plasma renin activity becomes a simple, albeit imperfect, surrogate marker for the effective arterial volume.19 Thus, the focus could shift from the absolute value of the plasma renin activity to an assessment of ENaC activity during dietary salt surfeit in which the normal physiological response would be to downregulate ENaC activity. Along these lines, the article by Fisher et al2 demonstrates striking functional similarities between LREH and NMEH, which in the present interpretation become somewhat arbitrarily differentiated on the basis of the plasma renin activity.

Despite apparent mineralocorticoid excess, Liddle’s syndrome is not necessarily associated with overt hypokalemia,12 which is similar to patients with glucocorticoid-remediable aldosteronism.20 Nevertheless, enhanced urinary potassium excretion was present in the affected subjects, which became even more evident when the overnight urinary aldosterone excretion was factored by the potassium excretion.12 Previous studies have demonstrated suppression of aldosterone excretion in juvenile black subjects,21 and more recent studies have demonstrated increased overnight urinary aldosterone to potassium ratios in these black subjects, suggesting that there was enhanced activity and/or responsiveness of collecting tubule ENaC to endogenous mineralocorticoid hormone.16 Although these data are not presented in the paper by Fisher et al,2 it would be of interest to know if the LREH and NMEH subjects could be further characterized by their overnight urinary aldosterone to potassium excretion ratios. The responses to mineralocorticoid receptor antagonists and angiotensin receptor antagonists are also of interest in LREH and NMEH. Such studies could determine if the adrenal responsiveness to Ang II accounts for the normal plasma aldosterone levels in these conditions and whether there is enhanced ENaC activity that is regulated by mineralocorticoids in these forms of human essential hypertension.

Footnotes

  • The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

References

  1. ↵
    Dunn MJ, Tannen RL. Low-renin hypertension. Kidney Int. 1974;5:317–315.
    OpenUrlPubMed
  2. ↵
    Fisher NDL, Hurwitz S, Ferri C, Jeunemaı̂tre X, Hollenberg NK, Williams GH. Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension. Hypertension. 1999;34:388–394.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med. 1993;153:2125–2129.
    OpenUrlCrossRefPubMed
  4. ↵
    Holland OB. Primary aldosteronism. Semin Nephrol.. 1995;15:116–125.
    OpenUrlPubMed
  5. ↵
    Flood C, Gherondache C, Pincus G, Tait JF, Tait SAS, Willoughby S. The metabolism and secretion of aldosterone in elderly subjects. J Clin Invest. 1967;46:960–966.
  6. ↵
    Scheinman SJ, Guay-Woodford LM, Thakker RV, Warnock DG. Genetic disorders of renal electrolyte transport. N Engl J Med. 1999;340:1177–1187.
    OpenUrlCrossRefPubMed
  7. ↵
    Rossier BC. 1996 Homer Smith Award Lecture. Cum grano salis: the epithelial sodium channel and the control of blood pressure. J Am Soc Nephrol. 1997;8:980–992.
    OpenUrlPubMed
  8. ↵
    Warnock DG. The epithelial sodium channel in hypertension. Curr Hypertens Rep. 1999;1:158–163.
    OpenUrlPubMed
  9. ↵
    Lifton RP. Molecular genetics of human blood pressure variation. Science. 1996;272:676–680.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JRJ, Ulick S, Milora RV, Findling JW, Canessa CM, Rossier BC, Lifton RP. Liddle’s syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell. 1994;79:407–414.
    OpenUrlCrossRefPubMed
  11. ↵
    Jeunemaitre X, Bassilana F, Persu A, Dumont C, Champigny G, Lazdunski M, Corvol P, Barbry P. Genotype-phenotype analysis of a newly discovered family with Liddle’s syndrome. J Hypertens. 1997;15:1091–1100.
  12. ↵
    Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle’s syndrome revisited. New Eng J Med. 1994;330:178–181.
    OpenUrlCrossRefPubMed
  13. ↵
    Gadallah MF, Abreo K, Work J. Liddle’s syndrome: an under-recognized entity; a report of four cases including the first report in black individuals. Am J Kidney Dis. 1995;25:924–927.
    OpenUrlPubMed
  14. ↵
    Cui Y, Su YR, Rutkowski M, Reif M, Menon AG, Pun RYK. Loss of protein kinase C inhibition in the β-T594 M variant of the amiloride-sensitive Na+ channel. Proc Natl Acad Sci U S A. 1997;94:9962–9966.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Baker EH, Dong YB, Sagnella GA, Rothwell M, Onipinia AK, Markandu ND, Cappuccio FP, Cook DG, Persu A, Corvol P, Jeunemaitre X, Carter ND, MacGregor GA. Association of hypertension with T594 M mutation in the β subunit of epithelial sodium channels in black people resident in London. Lancet.. 1998;351:1388–1392.
    OpenUrlCrossRefPubMed
  16. ↵
    Ambrosius WT, Bloem U, Zhou L, Rebhun JF, Snyder PM, Wagner MA, Guo C, Pratt JH. Variations in the amiloride-sensitive epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension. Hypertension.1999;34: In press.
  17. ↵
    Warnock DG. Liddle syndrome: an autosomal dominant form of human hypertension. Kidney Int. 1998;53:l8–24.
    OpenUrl
  18. ↵
    Liddle GW, Bledsoe T, Coppage WS. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Amer Assoc. Physicians. 1963;76:199–213.
  19. ↵
    Guyton AC. Blood pressure control: special role of the kidneys and body fluids. Science. 1991;252:1813–1816.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Rich G, Ulick S, Cook S, Wang J, Lifton R, Dluhy R. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann lnt Med. 1992;116:813–820.
  21. ↵
    Pratt JH, Jones JJ, Miller JZ, Wagner MA, Fineberg NS. Racial differences in aldosterone excretion and plasma aldosterone concentrations in children. N Engl J Med. 1989;321:1152–1157.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
September 1999, Volume 34, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Low-Renin and Nonmodulating Essential Hypertension
    David G. Warnock
    Hypertension. 1999;34:395-397, originally published September 1, 1999
    https://doi.org/10.1161/01.HYP.34.3.395

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Low-Renin and Nonmodulating Essential Hypertension
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Low-Renin and Nonmodulating Essential Hypertension
    David G. Warnock
    Hypertension. 1999;34:395-397, originally published September 1, 1999
    https://doi.org/10.1161/01.HYP.34.3.395
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Genetics
    • Genetics
  • Basic, Translational, and Clinical Research
    • Etiology

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured